| 名稱 | HHLA2(B7H7) aAPC Cell |
| 型號(hào) | CBP74194 |
| 報(bào)價(jià) |  |
| 特點(diǎn) | HHLA2(B7H7) aAPC Cell |
產(chǎn)品搜索
相關(guān)文章
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > 腫瘤免疫細(xì)胞株 > CBP74194HHLA2(B7H7) aAPC Cell
- 詳細(xì)內(nèi)容
| CBP74194 | |
| I. Background | |
| HHLA2 (a B7 family member) has both immune inhibitory and activating abilities and is expressed in many human cancers. These differing functions rely on the receptor to which it binds, yet many of these receptors are uncharacterized. Here, Wei et al. found that KIR3DL3 bound to HHLA2 and was expressed on effector memory CD8+ T cells and CD56dim NK cells. Interactions of KIR3DL3 with tumoral HHLA2 inhibited the function and killing capacity of both CD8+ T cells and NK cells. KIR3DL3+ immune cells infiltrated various types of HHLA2+ tumors from patients with cancer, and blockade of KIR3DL3 inhibited the growth of tumors in various mouse models. Thus, KIR3DL3-HHLA2 inhibits immune-mediated clearance of tumor cells and presents a possible immunotherapeutic target for cancer. | |
| II. Introduction | |
| Expressed gene: | HHLA2(B7H7) |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | F12K+10%FBS+2ug/ml puromycin+500ug/ml hygromycin |
| Mycoplasma Testing: | Negative |
| Storage: | Liquid nitrogen |
| Application(s): | Functional(Report Gene) Assay |
| III. Representative Data | |
Figure 1. Dose Response of HHLA2 Blocking Abs in KIR3DL3 Effector Reporter Cells (C1)With HHLA2(B7H7) aAPC Cells. | |
會(huì)員_a.png)